Pacific Edge Ltd has appointed Darrell Morgan as Chief Operating Officer following an executive search conducted by SEQEL Partners.

Pacific Edge is a cancer diagnostics company listed on both the NZX and ASX, specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer.
 
Darrell has extensive experience in senior leadership and executive roles in large, mid-sized and virtual pharmaceutical companies in the UK, Europe and New Zealand. He has more than 37 years’ experience in pharmaceutical R&D, immunodiagnostics and device development for drug delivery across human and animal health, in R&D, technical operations and customer-facing roles. Since 2013, Darrell has been a senior leader with animal health company Argenta Research where his roles have included Global Head of Pharmaceutical Sciences, VP Customer Relationships – Pharmaceutical Sciences, and Product Development Director – Technical Operations. Prior to Argenta Research, Darrell worked for global biopharmaceutical company UCB in the UK for eight years in senior roles with a focus on sterile drug product and medical device development.
 
Darrell is a chartered biologist, with post graduate diplomas in industrial pharmaceutical sciences and management, people and change.
 
As Chief Operating Officer, Darrell will be responsible for Pacific Edge’s global laboratory operations, manufacturing, logistics, inventory management, the quality and regulatory compliance functions and operationalising people and culture initiatives. He will have a focus on project management, people and culture, and operational excellence to optimise effectiveness, efficiency and on time delivery of products and services.
 
Darrell joins Pacific Edge in October 2022 as a key member of the executive team and will be based in Dunedin.